Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560


Company Overview

Corporate Profile
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 1.45 (3.26%)
Data as of 11/24/17 1:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
11/14/17Pacira Announces FDA Advisory Committee Meeting to Review sNDA for EXPAREL® as a Nerve Block for Regional Analgesia
PARSIPPANY, N.J., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that its supplemental New Drug Application (sNDA) for EXPAREL® (bupivacaine liposome injectable suspension) as a nerve block for regional analgesia will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC).  The meeting is tentatively scheduled for February 14-15, 2... 
Printer Friendly Version
11/09/17Pacira Pharmaceuticals to Present at Two November Healthcare Conferences
PARSIPPANY, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the following two healthcare conferences: Jefferies 2017 Healthcare Conference in London, on Thursday, November 16, 2017 at 10:00 AM GMT (5:00 AM ET) Piper Jaffray 29th Annual Healthcare Conference in New York City, on Wednesday, November 29, 2017 at 10:00 AM ET A live audio webcast of the Pacira presentation... 
Printer Friendly Version
11/08/17Pacira Pharmaceuticals, Inc. Reports Third Quarter 2017 Financial Results
EXPAREL(R) net product sales of $66.8 million up 3% over prior year third quarter; Full-year EXPAREL net product sales guidance revised to $280 to $285 million; Conference Call Today at 8:30 a.m. ET PARSIPPANY, NJ -- (Marketwired) -- 11/08/17 -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the third quarter ended September 30, 2017. "We continue to make important progress during 2017 as we advance our strategy to expand the ro... 
Printer Friendly Version
10/31/17Pacira Pharmaceuticals Announces Timing for Third Quarter 2017 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Wednesday November 8, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team. The call can be accessed by dialin... 
Printer Friendly Version

Corporate Presentation

There are currently no items available.
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Contact Investor Relations:
Susan Mesco
(973) 451-4030

IHI/NPSF Project Seeks to Improve the Assessment and Management of Acute Pain
Click here for more...